Literature DB >> 17922394

A framework for assessing immunological correlates of protection in vaccine trials.

Li Qin1, Peter B Gilbert, Lawrence Corey, M Juliana McElrath, Steven G Self.   

Abstract

A central goal of vaccine research is to identify a vaccine-induced immune response that predicts protection from infection or disease. The term "correlate of protection" has been used to refer to at least 3 distinct concepts, which has resulted in confusion surrounding this topic. We propose precise definitions of these different concepts of immune correlates, using the nomenclature "correlate of risk," "level 1 surrogate of protection," and "level 2 surrogate of protection." We suggest a general framework for assessing these 3 levels of immune correlates in vaccine efficacy trials. To demonstrate the proposed principles, we analyze data from a 1943 influenza vaccine field trial, supporting Weiss strain A-specific antibody titers as a level 1 surrogate of protection. Other real and simulated examples are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922394     DOI: 10.1086/522428

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  97 in total

1.  Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.

Authors:  Peter B Gilbert; Michael G Hudgens; Julian Wolfson
Journal:  Int J Biostat       Date:  2011-09-20       Impact factor: 0.968

2.  Nomenclature for immune correlates of protection after vaccination.

Authors:  Stanley A Plotkin; Peter B Gilbert
Journal:  Clin Infect Dis       Date:  2012-03-20       Impact factor: 9.079

Review 3.  The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors.

Authors:  Richard A Koup; Barney S Graham; Daniel C Douek
Journal:  Nat Rev Immunol       Date:  2010-12-17       Impact factor: 53.106

4.  A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.

Authors:  Laurent Coudeville; Philippe Andre; Fabrice Bailleux; Françoise Weber; Stanley Plotkin
Journal:  Hum Vaccin       Date:  2010-10-01

5.  Augmented trial designs for evaluation of principal surrogates.

Authors:  Erin E Gabriel; Dean Follmann
Journal:  Biostatistics       Date:  2016-01-28       Impact factor: 5.899

Review 6.  A history of hookworm vaccine development.

Authors:  Brent Schneider; Amar R Jariwala; Maria Victoria Periago; Maria Flávia Gazzinelli; Swaroop N Bose; Peter J Hotez; David J Diemert; Jeffrey M Bethony
Journal:  Hum Vaccin       Date:  2011-11-01

7.  Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2009-02-15       Impact factor: 2.373

8.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

Review 9.  Efficacy of the vaccination in inflammatory bowel disease.

Authors:  Elisa Carrera; Rebeca Manzano; Elena Garrido
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

10.  HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.

Authors:  James G Kublin; Cecilia A Morgan; Tracey A Day; Peter B Gilbert; Steve G Self; M Juliana McElrath; Lawrence Corey
Journal:  Clin Investig (Lond)       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.